Table II.
Published AUC Ratios Used for the External Validation Step
| Drug | Genotype | FAa | Number of subjects | Observed AUC ratio | Reference |
|---|---|---|---|---|---|
| Amitriptyline | *1*2 | 0.5 | 18 | 1.29 | (32) |
| Citalopram | *2*2 | 0.01 | 5 | 1.23 | (51) |
| Citalopram | *1*2 | 0.5 | 7 | 1.44 | (33) |
| Cilostazol | *1*2 | 0.5 | 18 | 1.2 | (34) |
| Clomipramine | *1*2 | 0.5 | 25 | 1.41 | (35) |
| Clopidogrel | *1*2 | 0.5 | 8 | 1.67 | (36) |
| Diazepam | *1*2 | 0.5 | 6 | 2.47 | (37) |
| Escitalopram | *17*17 | 2.25 | 5 | 0.79 | (52) |
| Fluoxetine | *1*2 | 0.5 | 4 | 1.58 | (39) |
| Gliclazide | *2*2 | 0.01 | 3 | 3.42 | (53) |
| Gliclazide | *1*2 | 0.5 | 12 | 1.25 | (53) |
| Lansoprazole | *2*2 | 0.01 | 3 | 1.88 | (54) |
| Lansoprazole | *2*2 | 0.01 | 4 | 5.41 | (55) |
| Lansoprazole | *2*2 | 0.01 | 6 | 4.03 | (56) |
| Lansoprazole | *1*2 | 0.5 | 5 | 1.67 | (41) |
| Lansoprazole | *1*2 | 0.5 | 2 | 1.32 | (54) |
| Lansoprazole | *1*2 | 0.5 | 7 | 2.31 | (55) |
| Lansoprazole | *1*2 | 0.5 | 7 | 2.14 | (58) |
| Lansoprazole | *1*2 | 0.5 | 4 | 1.68 | (21) |
| Lansoprazole | *1*2 | 0.5 | 6 | 1.78 | (56) |
| Lansoprazole | *1*17 | 1.63 | 1 | 0.45 | (21) |
| Lansoprazole | *2*17 | 1.13 | 1 | 1.34 | (21) |
| Lansoprazole R | *1*2 | 0.5 | 6 | 1.46 | (17) |
| Lansoprazole S | *1*2 | 0.5 | 6 | 1.85 | (17) |
| Mephobarbital R | *1*2 | 0.5 | 10 | 4.4 | (42) |
| Nelfinavir | *1*2 | 0.5 | 22 | 1.49 | (44) |
| Nelfinavir active moietyb | *1*2 | 0.5 | 22 | 1.29 | (44) |
| Omeprazole | *2*2 | 0.01 | 6 | 7.42 | (58) |
| Omeprazole | *2*2 | 0.01 | 6 | 2.03 | (16) |
| Omeprazole | *2*2 | 0.01 | 6 | 9.03 | (59) |
| Omeprazole | *2*2 | 0.01 | 6 | 3.8 | (21) |
| Omeprazole | *2*2 | 0.01 | 6 | 7.54 | (56) |
| Omeprazole | *2*2 | 0.01 | 6 | 7.79 | (60) |
| Omeprazole | *2*2 | 0.01 | 8 | 5.68 | (61) |
| Omeprazole | *1*2 | 0.5 | 5 | 2.29 | (45) |
| Omeprazole | *1*2 | 0.5 | 6 | 1.72 | (58) |
| Omeprazole | *1*2 | 0.5 | 8 | 2.66 | (59) |
| Omeprazole | *1*2 | 0.5 | 2 | 3.67 | (21) |
| Omeprazole | *1*2 | 0.5 | 6 | 2.84 | (56) |
| Omeprazole | *1*2 | 0.5 | 6 | 2.85 | (60) |
| Omeprazole | *1*17 | 1.63 | 1 | 0.77 | (21) |
| Omeprazole | *2*17 | 1.13 | 1 | 1.83 | (21) |
| Pantoprazole | *1*2 | 0.5 | 7 | 2.16 | (62) |
| Pantoprazole | *1*2 | 0.5 | 2 | 4.2 | (21) |
| Pantoprazole | *1*17 | 1.63 | 1 | 0.79 | (21) |
| Pantoprazole | *2*17 | 1.13 | 1 | 1.41 | (21) |
| Proguanil | *1*2 | 0.5 | 5 | 2.99 | (47) |
| Rabeprazole | *2*2 | 0.01 | 6 | 3.13 | (63) |
| Rabeprazole | *2*2 | 0.01 | 4 | 5.26 | (45) |
| Rabeprazole | *2*2 | 0.01 | 4 | 4.34 | (64) |
| Rabeprazole | *2*2 | 0.01 | 6 | 3.73 | (56) |
| Rabeprazole | *2*2 | 0.01 | 5 | 2.68 | (65) |
| Rabeprazole | *1*2 | 0.5 | 5 | 1.71 | (41) |
| Rabeprazole | *1*2 | 0.5 | 8 | 1.38 | (63) |
| Rabeprazole | *1*2 | 0.5 | 5 | 3.02 | (45) |
| Rabeprazole | *1*2 | 0.5 | 6 | 2.05 | (64) |
| Rabeprazole | *1*2 | 0.5 | 6 | 1.57 | (56) |
| Rabeprazole | *1*2 | 0.5 | 8 | 1.1 | (65) |
| Sertraline | *1*2 | 0.5 | 22 | 1.4 | (22) |
| Sertraline | *17*17 | 2.25 | 5 | 0.99 | (22) |
| Sertraline | *1*17 | 1.63 | 40 | 1.1 | (22) |
| Sertraline | *2*17 | 1.13 | 7 | 1.9 | (22) |
| Sibutramine | *1*2 | 0.5 | 26 | 1.13 | (48) |
| Trimipramine | *1*2 | 0.5 | 7 | 2.04 | (49) |
| Voriconazole | *2*2 | 0.01 | 8 | 3.45 | (66) |
| Voriconazole | *2*2 | 0.01 | 5 | 2.78 | (23) |
| Voriconazole | *2*2 | 0.01 | 6 | 4.02 | (67) |
| Voriconazole | *2*2 | 0.01 | 4 | 2.90 | (68) |
| Voriconazole | *1*2 | 0.5 | 8 | 2.28 | (50) |
| Voriconazole | *1*2 | 0.5 | 11 | 1.56 | (23) |
| Voriconazole | *1*2 | 0.5 | 8 | 1.3 | (68) |
| Voriconazole | *1*2 | 0.5 | 6 | 2.88 | (67) |
| Voriconazole | *1*17 | 1.63 | 4 | 0.52 | (66) |
| Voriconazole | *1*17 | 1.63 | 8 | 0.82 | (23) |
| Voriconazole | *2*17 | 1.13 | 2 | 0.78 | (23) |
aInitial estimate of the fraction of CYP2C19 activity for each genotype, with respect to the reference genotype (*1*1)
bThe active moiety of nelfinavir is nelfinavir + M8 active metabolite (nelfinavir hydroxy-t-butylamide)